| Catalog No. | HB805026 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Mouse |
|---|
| Isotype | IgG1, kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Species | Human |
|---|
| Clonality | Monoclonal |
|---|
| Target | CD11A, Leukocyte function-associated molecule 1 alpha chain, Leukocyte adhesion glycoprotein LFA-1 alpha chain, LFA-1A, CD11 antigen-like family member A, CD11a, ITGAL, Integrin alpha-L |
|---|
| Endotoxin level | Please contact with the lab for this information. |
|---|
| Purity | >95% as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Accession | P20701 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
|---|
| Alternate Names | afolimomab, anti-LFA1, CAS: 159445-64-4 |
|---|
| Background | Odulimomab is an investigational monoclonal antibody designed to prevent transplant rejection and address various immune-related disorders. As a mouse-derived antibody, it specifically targets the alpha chain of lymphocyte function-associated antigen 1 (LFA-1), a key molecule in immune cell adhesion and activation. By modulating LFA-1 interactions, Odulimomab holds potential for regulating immune responses and mitigating pathological immune reactions. |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
